文献速递认知障碍与痴呆脑血管病

用队列数据模拟他汀类药物使用与痴呆风险的目标试验

Emulating a target trial of statin use and risk of dementia using cohort data.
PubMed 文献 · Neurology · 2020-08-04

该研究基于荷兰前瞻性队列,将55-80岁人群按月模拟为5个连续的目标试验,比较他汀起始与不起始、持续使用与不使用对痴呆风险的影响。结果显示持续使用他汀者10年痴呆或死亡联合终点风险降低,但起始他汀本身未见显著获益,作者提示因起始者与事件数较少需谨慎解读。

要点

  • 持续使用他汀者10年痴呆或死亡联合终点风险降低5.1%。
  • 他汀起始与不起始相比,10年痴呆风险差异无统计学意义。
  • 起始者仅622例、事件数少,结果需谨慎解释。

核心结论

  • 持续使用他汀者10年痴呆及痴呆或死亡风险降低,但仅起始他汀未见显著获益。

研究设计与样本

  • 基于荷兰前瞻性队列数据,模拟1993-2007年间55-80岁人群的连续月度目标试验。
  • 共纳入233,526人-试验(6,373人),其中起始者622人、非起始者232,904人。
  • 采用合并logistic回归估计风险,并用逆概率加权处理治疗-混杂因素反馈。

主要发现

  • 起始他汀与不起始相比,10年痴呆风险差为-0.1%(95%CI -2.3%至1.8%)。
  • 起始他汀与不起始相比,10年痴呆或死亡风险差为0.3%(95%CI -2.7%至3.3%)。
  • 持续使用与他汀不使用相比,10年痴呆风险差为-2.2%(95%CI -5.2%至1.6%)。
  • 持续使用与他汀不使用相比,10年痴呆或死亡风险差为-5.1%(95%CI -10.5%至-1.1%)。

临床怎么用

  • 对持续服用他汀的中老年患者,可关注其痴呆及死亡联合风险的潜在获益信号。
  • 不应仅基于起始他汀的观察性结果推断痴呆预防作用。
  • 解释此类目标试验模拟结果时需结合起始者少和残余混杂的局限。

局限性

  • 起始他汀者仅622例且痴呆事件数少,估计精度有限。
  • 观察性数据存在残余混杂可能,不能等同于随机试验结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Observational data can be used to attempt to emulate a target trial of statin use and estimate analogues of intention-to-treat and per protocol effects on dementia risk. METHODS: Using data from a prospective cohort study in the Netherlands, we conceptualized a sequence of "trials" in which eligible individuals ages 55-80 years were classified as statin initiators or noninitiators for every consecutive month between 1993 and 2007 and were followed until diagnosis of dementia, death, loss to follow-up, or the end of follow-up. We estimated 2 types of effects of statin use on dementia and a combined endpoint of dementia or death: the effect of initiation vs no initiation and the effect of sustained use vs no use. We estimated risk by statin treatment strategy over time via pooled logistic regression. We used inverse-probability weighting to account for treatment-confounder feedback in estimation of per-protocol effects. RESULTS: Of 233,526 eligible person-trials (6,373 individuals), there were 622 initiators and 232,904 noninitiators. Comparing statin initiation with no initiation, the 10-year risk differences (95% confidence interval) were -0.1% (-2.3% to 1.8%) for dementia and 0.3% (-2.7% to 3.3%) for dementia or death. Comparing sustained statin use vs no use, the 10-year risk differences were -2.2% (-5.2% to 1.6%) for dementia and -5.1% (-10.5% to -1.1%) for dementia or death. CONCLUSIONS: Individuals with sustained statin use, but not statin initiation alone, had reduced 10-year risks of dementia and dementia or death. Our results should be interpreted with caution due to the small number of initiators and events and potential for residual confounding.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Caniglia EC, Rojas-Saunero LP, Hilal S, et al. Emulating a target trial of statin use and risk of dementia using cohort data. Neurology. 2020. PMID: 32753444. doi:10.1212/WNL.0000000000010433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。